duan-aptamerbased-2017.pdf (2.12 MB)
Aptamer-based therapeutic approaches to target cancer stem cells
journal contribution
posted on 2017-01-01, 00:00 authored by G Zhou, O Latchoumanin, M Bagdesar, L Hebbard, Wei DuanWei Duan, C Liddle, J George, L QiaoCancer stem cells (CSCs) are believed to be a principal cellular source for tumour progression and therapeutic drug resistance as they are capable of self-renewal and can differentiate into cancer cells. Importantly, CSCs acquire the ability to evade the killing effects of cytotoxic agents through changes at the genetic, epigenetic and micro-environment levels. Therefore, therapeutic strategies targeting CSCs hold great potential as an avenue for cancer treatment. Aptamers or "chemical antibodies" are a group of single-stranded nucleic acid (DNA or RNA) oligonucleotides with distinctive properties such as smaller size, lower toxicity and less immunogenicity compared to conventional antibodies. They have been frequently used to deliver therapeutic payloads to cancer cells and have achieved encouraging anti-tumour effects. This review discusses progress in CSC evolution theory and the role of aptamers to target CSCs for cancer treatment. Challenges of aptamer-mediated CSC targeting approaches are also discussed.
History
Journal
TheranosticsVolume
7Issue
16Pagination
3948 - 3961Publisher
Ivyspring International PublisherLocation
Wyoming, N.S.W.Publisher DOI
Link to full text
eISSN
1838-7640Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2017, Ivyspring International PublishersUsage metrics
Categories
No categories selectedKeywords
CSCsantibodiesaptamerscancerdrug resistancenanoparticles.Science & TechnologyLife Sciences & BiomedicineMedicine, Research & ExperimentalResearch & Experimental MedicinenanoparticlesMESOPOROUS SILICA NANOPARTICLESBREAST-CANCERADHESION MOLECULEDRUG-DELIVERYIDENTIFICATIONHETEROGENEITYRESISTANCENANORODS
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC